Dr. Maria A. Levitin, MD

Dr. Levitin practices at Henry Ford Hospital in Detroit, Michigan, part of Henry Ford Health.

Dr. Levitin's NPI, 1366891707, was assigned on June 7, 2016. Dr. Levitin holds Michigan license 4301117382.

Dr. Levitin's primary practice is Henry Ford Hospital, at 2799 W Grand Blvd, Detroit, MI 48202 in Wayne County. The practice phone is (313) 916-2600.

Dr. Levitin's primary practice is Henry Ford Hospital in Detroit, Michigan, part of Henry Ford Health. Dr. Levitin is also affiliated with Henry Ford Macomb Hospital. The medical group on file is Henry Ford Health. Dmand AI also links Dr. Levitin to 2 more hospitals, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Levitin practices, 6 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Levitin's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Levitin is licensed in Michigan.

CMS data shows 354 Medicare services from Dr. Levitin across 5 procedure codes in 2021, for 18 Medicare patients. Medicare paid $25,796 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 18 Medicare patients who saw Dr. Levitin in 2024. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 2.25, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Levitin's median patient age at 67, with 49% women.

In 2024, Dr. Levitin wrote 186 Medicare Part D claims for 50 patients. 58% of them were for generic drugs. CMS names the drug for 67 of them, across 3 drugs with 11 or more claims each, at $83,883 in total drug cost. In 2023, CMS named 12 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Levitin for performance year 2024, reported through an alternative payment model (APM). Dr. Levitin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Levitin as offering telehealth.

Dmand AI links 2 papers to Dr. Levitin, published from 2020 to 2023. Dr. Levitin's most frequent co-authors are Hadeel Salim Assad, MD and Mackenzie D. Daly, MD.

CMS Open Payments shows 3 general payments to Dr. Levitin from 3 drug and device companies from 2018 to 2024. Food and beverage make up the largest share, 100% of the total. Novocure Inc. paid the most, $125.